About Wytech Pharmaceuticals
Wytech Pharmaceuticals is a Healthcare company. Pharmaceutical manufacturing with a focus on Cardiology and CNS therapies in India. Its Indian entity Wytech Pharmaceuticals Private Limited reported revenue of ₹1.52 Cr. Wytech Pharmaceuticals offers products and services including Nitrojet and Rozunice. Its focus areas include Pharmaceuticals, Drug Manufacturing, Cardiology and CNS.
Company details
Wytech Pharmaceuticals Pvt. Ltd. is recognized for its operations in manufacturing pharmaceutical products, particularly in Cardiology and CNS areas, with products being produced in WHO GMP-certified plants to meet international standards. It is led by professionals who have gained experience from reputed Indian and multinational companies, emphasizing cost-effective pricing and partnerships with doctors, retailers, and wholesalers. Established in 2016, efforts are directed towards providing high-quality medicines at reasonable prices to address unmet medical needs globally, while upholding core values of knowledge, action, and care. An excellent team is employed to drive success in these therapies.
- SectorsHealthcare
- Email••••••••
- Legal Name Wytech Pharmaceuticals Pvt Ltd
- Date of Incorporation 09 Nov, 2015
- Jurisdiction Chandigarh, India
- Indian entity revenue₹1.52 Cr
FY 2025 · -8% YoY
- Indian entity net profit₹3.3 Lakh
FY 2025 · 2% margin
- Indian entity EBITDA₹13.7 Lakh
FY 2025 · 9% margin
Associated legal entities of Wytech Pharmaceuticals
Wytech Pharmaceuticals operates through Wytech Pharmaceuticals Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Wytech Pharmaceuticals Private Limited CIN U24233CH2015PTC035814 | Active | 09 Nov 2015 | Chandigarh, Chandigarh | ₹1.5 Cr | 3 | View details |
Products & Services of Wytech Pharmaceuticals
Wytech Pharmaceuticals offers a comprehensive portfolio of products and services, including Nitrojet and Rozunice.
Nitrojet is offered for cardiovascular treatments, with manufacturing processes that ensure compliance with international standards.
Rozunice is provided for central nervous system disorders, drawing on expertise from professionals with backgrounds in reputed companies.
Board of directors of Wytech Pharmaceuticals Private Limited (Wytech Pharmaceuticals)
Wytech Pharmaceuticals Private Limited is the primary company behind Wytech Pharmaceuticals. The board of Wytech Pharmaceuticals Private Limited currently have 3 directors; the longest-serving is Satbir Singh, appointed in 2015. 1 earlier director has ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Satbir Singh DIN 07334045 | Director | 09 Nov 2015 | 10 yrs 11 mo | Wytech Pharmaceuticals Private Limited |
| Hemdeep Singh DIN 07334053 | Director | 09 Nov 2015 | 10 yrs 11 mo | Wytech Pharmaceuticals Private Limited |
| Manmohan Singh Saggu DIN 09833518 | Director | 22 Dec 2022 | 3 yrs 10 mo | Wytech Pharmaceuticals Private Limited |
Financials of Wytech Pharmaceuticals
Figures of Wytech Pharmaceuticals Private Limited, the primary company behind Wytech Pharmaceuticals, for FY 2025. Revenue was ₹1.52 Cr (-8% year on year). Net profit was ₹3.3 Lakh (2% margin). EBITDA was ₹13.7 Lakh (9% margin). Revenue has grown at a compounded annual rate of +6% over three years and -1% over five years.
- ₹1.52 CrRevenue · FY 2025 · -8% YoY
- ₹3.3 LakhNet profit · 2% margin
- ₹13.7 LakhEBITDA · 9% margin
- ₹1 LakhPaid-up capital
- +6%Revenue CAGR, 3 years
- -1%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Wytech Pharmaceuticals Private Limited are on its company page.
Detailed financial statements for Wytech Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Wytech Pharmaceuticals
The primary company behind Wytech Pharmaceuticals, Wytech Pharmaceuticals Private Limited, reported revenue of ₹1.52 Cr for FY 2025, down 8% year on year.
Wytech Pharmaceuticals Pvt. Ltd. is recognized for its operations in manufacturing pharmaceutical products, particularly in Cardiology and CNS areas, with products being produced in WHO GMP-certified plants to meet international standards. It is led by professionals who have gained experience from reputed Indian and multinational companies, emphasizing cost-effective pricing and partnerships with doctors, retailers, and wholesalers. Established in 2016, efforts are directed towards providing high-quality medicines at reasonable prices to address unmet medical needs globally, while upholding core values of knowledge, action, and care. An excellent team is employed to drive success in these therapies.
Wytech Pharmaceuticals offers Nitrojet and Rozunice.
Wytech Pharmaceuticals operates through Wytech Pharmaceuticals Private Limited.
The legal entities of Wytech Pharmaceuticals currently have 3 directors, including Satbir Singh, Hemdeep Singh, Manmohan Singh Saggu.